Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum toxin A pelvic floor injection for refractory chronic pelvic pain
NL-OMON20966Not yet recruiting
- Sponsor
- Radboudumc
- Start
- Jul 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, double-blind trial of botulinum toxin type A in chronic prostatitis (CP) and Pelvic floor hypertonicity (PFH) (2 arms), sponsored by Radboudumc. Primary endpoint: Primary pain response. Planned start Jul 2017; status: not yet recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
chronic prostatitis (CP)Pelvic floor hypertonicity (PFH)
Beyond the preview
Go deeper on NL-OMON20966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON20966.